Agios Pharmaceuticals | AGIO - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Arrowhead Research USD 201.64M 112.94M 2025-12
Astellas Pharma JPY 188.37B 8.51B 2025-03
AstraZeneca USD 5.71B 2.43B 2025-12
Bayer EUR 5.9B 1.34B 2025-09
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
Eli Lilly USD 7.27B 2.52B 2025-12
Exelixis USD 482.49M 106.19M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.15B 146M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Novartis USD 11.44B 1.88B 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12